Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $42.4286.

VRDN has been the topic of several recent analyst reports. UBS Group assumed coverage on Viridian Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $61.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Needham & Company LLC lifted their target price on shares of Viridian Therapeutics from $34.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. The Goldman Sachs Group reissued a “buy” rating and issued a $40.00 price target on shares of Viridian Therapeutics in a report on Thursday, November 6th. Finally, William Blair began coverage on shares of Viridian Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating on the stock.

Insider Transactions at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.58% of the stock is currently owned by company insiders.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of VRDN. Simplify Asset Management Inc. bought a new position in shares of Viridian Therapeutics during the third quarter valued at about $1,079,000. Corton Capital Inc. bought a new stake in shares of Viridian Therapeutics in the 2nd quarter valued at about $248,000. Moody Aldrich Partners LLC boosted its holdings in Viridian Therapeutics by 54.2% during the 2nd quarter. Moody Aldrich Partners LLC now owns 89,164 shares of the company’s stock valued at $1,247,000 after acquiring an additional 31,323 shares during the period. Rice Hall James & Associates LLC grew its position in Viridian Therapeutics by 65.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company’s stock worth $18,379,000 after acquiring an additional 336,040 shares during the last quarter. Finally, J. Safra Sarasin Holding AG increased its stake in Viridian Therapeutics by 135.5% in the 2nd quarter. J. Safra Sarasin Holding AG now owns 171,119 shares of the company’s stock worth $2,392,000 after purchasing an additional 98,447 shares during the period.

Viridian Therapeutics Stock Down 0.4%

Shares of NASDAQ:VRDN opened at $32.17 on Friday. The firm has a fifty day moving average price of $31.61 and a two-hundred day moving average price of $24.02. The company has a market cap of $3.07 billion, a price-to-earnings ratio of -10.65 and a beta of 0.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.28 and a quick ratio of 11.28. Viridian Therapeutics has a one year low of $9.90 and a one year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.48. The firm had revenue of $70.57 million for the quarter, compared to analysts’ expectations of $16.21 million. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The company’s revenue was up 81993.0% on a year-over-year basis. Analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.